|
Pancreatica Trial ID |
Trial Name |
Trial Phase |
Trial Location |
|
|
PA-6660 |
Evaluation
of Treatment with Alfa-interferon, Octreotide or Their Combination
in Patients with Zollinger-Ellison Syndrome, Pancreatic Tumors
and Progressive Metastatic Non-B Islet Cell Neoplasm. |
Phase 2 |
Bethesda, MD, US |
|
|
|
|
|
|
PA-6709 |
Phase
II Study of Antineoplastons A10 and AS2-1 in Patients with Metastatic
or Incurable Neuroendocrine Tumors. |
Phase 2 |
Houston, TX, US |
|
|
|
|
|
|
PA-6768 |
Phase
II Study of CPT-11 in Patients with Metastatic, Unresectable
Carcinoid Tumors or Islet Cell Carcinoma. |
Phase 2 |
Houston, TX, US |
|
|
|
|
|
|
PA-6957 |
Phase
II Study of Paclitaxel, Carboplatin and Oral Etoposide Followed
by Weekly Paclitaxel in the Treatment of High-grade Neuroendocrine
Carcinoma. |
Phase 2 |
Huntsville, AL, US
Nashville, TN, US |
|
|
|
|
|
|
PA-7206 |
Phase
I Pilot Study of Flavopiridol in Patients With Locally Advanced
or Metastatic Neuroendocrine Tumors. |
Phase 1 |
Columbus, OH, US |
|
|
|
|
|
|
PA-7210 |
A
Pilot Study of FOLFOX in Combination with Bevacizumab in Patients
with Advanced Neuroendocrine Tumors. |
Phase 2 |
San Francisco, CA, US |
|
|
|
|
|
|
PA-7298 |
Phase
I/II Pilot Study of Fluorouracil, Leucovorin Calcium, and Oxaliplatin
(FOLFOX) With Bevacizumab in Patients With Advanced Neuroendocrine
Tumors. |
Phase 1 / 2 |
San Francisco, CA, US |
|
|
|
|
|
|
PA-7367 |
Phase
II Study of Capecitabine and Temozolomide For Progressive, Differentiated,
Metastatic Neuroendocrine Cancers. |
Phase 2 |
New York, NY, US |
|
|
|
|
|
|
PA-7537 |
Safety
and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine
Tumors. |
Phase 3 |
Houston, TX, US |
|
|
|
|
|
|
PA-7538 |
Study
to Investigate the Antiproliferative Effect of Octreotide in
Patients With Metastasized Neuroendocrine Tumors of the Midgut. |
Phase 3 |
Marburg, Germany |
|
|
|
|
|
|
PA-7539 |
Study
of Lanreotide Autogel in Non-Functioning Entero-Pancreatic Endocrine
Tumours. |
Phase 3 |
Prague, Czech Republic
London, England
Clichy, France
Lille , France
Marseille, France
Reims, France
Villejuif , France
Bologna, Italy
Milan, Italy
Barcelona, Spain |
|
|
|
|
|
|
PA-7540 |
Everolimus
and Octreotide in Patients With Advanced Carcinoid Tumor. |
Phase 3 |
Fayetteville, AR, US |
|
|
|
|
|
|
PA-7541 |
Phase
I/II Study of BB-10901 in Patients With Recurrent or Refractory
Small Cell Lung Cancer, CD56-Positive Small Cell Carcinoma of
Unknown Origin, Other Pulmonary Tumors of Neuroendocrine Origin,
Non-Pulmonary Small Cell Carcinoma, Metastatic Carcinoid Tumor,
or Other CD56+ Solid Tumors (Phase I portion completed; patients
with refractory small cell lung cancer, other pulmonary tumors
of neuroendocrine origin, CD56-negative non-pulmonary small cell
carcinomas, metastatic carcinoid tumors, or other CD56+ solid
tumors are no longer being accrued as of 10/19/2005). |
Phase 2 |
Denver, CO, US
Ocoee , FL, US
Springfield, MA, US
Albany, NY, US
Columbus, OH, US
Kettering, OH, US
Greenville, SC, US
Houston, TX, US
Tyler, TX, US
Norfolk , VA, US
Vancouver, WA, US |
|
|
|
|
|
|
PA-7548 |
A
Combination Study to Determine the Safety and Efficacy of Panzem
NCD With Avastin in Metastatic Carcinoid Tumors. |
Phase 2 |
Boston, MA, US |
|
|
|
|
|
|
PA-7549 |
Irinotecan
and Cisplatin for High Grade Neuroendocrine Carcinoma of the
Gastrointestinal Tract. |
Phase 2 |
Houston, TX, US |
|
|
|
|
|
|
PA-7550 |
Safety
and Efficacy of Atiprimod Treatment for Patients With Low to
Intermediate Grade Neuroendocrine Carcinoma. |
Phase 2 |
Little Rock , AR, US
Tampa, FL, US
Chicago, IL, US
Boston, MA, US
Burlington, MA, US
New York, NY, US
Temple, TX, US |
|
|
|
|
|
|
PA-7551 |
Phase
II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic
/ Unresectable Neuroendocrine Tumors. |
Phase 2 |
Stanford, CA, US |
|
|
|
|
|
|
PA-7553 |
Phase
II Study of Pazopanib Hydrochloride in Patients With Low- or
Intermediate-Grade Advanced Neuroendocrine Carcinoma. |
Phase 2 |
Boston, MA, US
Houston, TX, US |
|
|
|
|
|
|
PA-7554 |
A
Study of Avastin (Bevacizumab) in Combination With Chemotherapy
in Patients With Endocrine Tumors of the Gastrointestinal Tract. |
Phase 2 |
Poitiers, France |
|
|
|
|
|
|
PA-7555 |
Phase
II Study of Selective Internal Radiation Therapy With Yttrium
Y 90 Resin Microspheres (Sir-Spheres®) in Patients With Symptomatic
or Progressive Hepatic Metastases From Neuroendocrine Tumors. |
Phase 2 |
Nashville, TN, US |
|
|
|
|
|
|
PA-7557 |
Safety
Study of Seneca Valley Virus in Patients With Solid Tumors With
Neuroendocrine Features. |
Phase 1 |
Ocoee , FL, US
Indianapolis , IN, US
Baltimore, MD, US
Albany, NY, US
Kettering, OH, US
Greenville, SC, US
Tyler, TX, US
Norfolk , VA, US
Vancouver, WA, US |
|
|
|
|
|
|
PA-7558 |
Phase
I Study of BB-10901 in Patients With Relapsed or Refractory Small
Cell Lung Cancer, Other Pulmonary Tumors of Neuroendocrine Origin,
Non-Pulmonary Small Cell Carcinoma, Metastatic Carcinoid Tumors,
or Other CD56-Positive Solid Tumors. |
Phase 1 |
Springfield, MA, US
Houston, TX, US
Manchester , England
Sheffield, England
Sutton, Surrey, England |
|
|
|
|
|
|
PA-7559 |
ULTRATRACE
Iobenguane I 131 in Patients With Malignant Pheochromocytoma,
Paraganglioma, or Metastatic Carcinoid. |
Phase 1 |
Durham, NC, US |
|
|
|
|
|
|
PA-7560 |
Effectiveness
of Octreotide in Patients With Metastasized Neuroendocrine Tumors
of the Midgut. |
Phase 3 |
Marburg , Germany |
|
|
|
|
|
|
PA-7561 |
Prospective
Evaluation Study of Tumor Angiogenesis in Patients With Endocrine
Neoplasms. |
Unspecified |
Bethesda, MD, US |
|
|
|
|
|
|
PA-7563 |
Phase
1-2 Study of Iobenguane (MIBG) I 131 in Patients With Malignant
Pheochromocytoma/Paraganglioma. |
Phase 2 |
|
|
|
|
|
|
